Slide 1: Good start for external innovation with new business mix
Good start for external innovation with new business mix Evotec AG, First Quarter 2018 Results, 09 May 2018
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Welcome to Q1 – Your Management Team
Welcome to Q1 Your Management Team Werner Lanthaler Enno Spillner Mario Polywka Cord Dohrmann CEO1) CFO1) COO1) CSO1) PAGE 2 1) On the call for the Quarterly Statement Q1 2018
Slide 4: Agenda
Agenda Highlights Q1 EVT Execute EVT Innovate Financial performance and outlook PAGE 3
Slide 5: Good start into 2018 – Strong FY outlook confirmed
Good start into 2018 – Strong FY outlook confirmed First three months 2018 – State of play EVT Execute EVT Innovate Corporate Significant progress within Alliance with Sanofi to Aptuit integration according ongoing alliances accelerate infectious to plan disease R&D1) Launch of INDiGO soluti
Slide 6: Strong performance in base business with new business mix after Aptuit acquisition
Strong performance in base business with new business mix after Aptuit acquisition Financial highlights Q1 2018 & FY Guidance Good start; milestones not in so far “3x30” – Confirmed guidance 2018 Group revenues up 55% to € 79.0 m More than 30% Group revenue growth (Q1 2017: € 50.9 m) (2017: € 25
Slide 7: Leading external innovation – Action Plan 2022
Leading external innovation “Action Plan 2022 – Leading External Innovation” 2022 2018 2012 2009 Sustainable profitability with positive Business segmentation operating cash flows including milestone and royalty potential Investments to build a world-class Restructuring service platform No
Slide 8: Agenda
Agenda Highlights Q1 EVT Execute EVT Innovate Financial performance and outlook PAGE 7
Slide 9: ONE platform for external innovation
ONE platform for external innovation Unique business model – EVT Execute & EVT Innovate PAGE 8
Slide 10: Strong organic and inorganic growth in EVT Execute
Strong organic and inorganic growth in EVT Execute EVT Execute – Key performance indicators Q1 2018 Revenues Adjusted EBITDA1) Increase in EVT Execute (in € m) (in € m) revenues mainly attributable to growth in the base business Base revenues +62% 78.5 +38% 17.2 and three months Aptuit Intersegmen
Slide 11: Healthy, slightly altered customer base following Aptuit acquisition
Healthy, slightly altered customer base following Aptuit acquisition EVT Execute – Selected KPIs Q1 2018 Revenues by customer Customer type ytd1) Revenues by region ytd1) segment ytd1) (in %) (in %) (in %) 100% 3% 100% Mid-sized 9% 100% RoW 2% Remaining 15% Pharma 15% Foun- 12% Top 11-30 41% 9% 38%
Slide 12: High quality and efficiency in R&D
High quality and efficiency in R&D EVT Execute – Major achievements Q1 2018 Significant progress within ongoing alliances (e.g. start of third clinical Phase I study in endometriosis with Bayer (after period-end)) Launch of INDiGO solution to accelerate drug candidate delivery; first alliances e
Slide 13: Industry-leading effort in endometriosis
Industry-leading effort in endometriosis Clinical stage pipeline and more to come Multi-target alliance with Bayer in Endometriosis/Pain Painful, debilitating reproductive condition affecting approximately 176 million women worldwide Focus on non-hormonal treatments in endometriosis Goal: Outp
Slide 14: "One stop partner" for external innovation
“One stop partner” for external innovation Evotec’s integrated offering and core competences along the value chain Pre- Hit- Lead Target ID/ clinical identi- optimi- IND Phase I Phase II Phase III Approval Market validation Tox fication sation testing Evotec offers end-to-end platform solutions incl
Slide 15: Integration of Aptuit progressing as planned
Integration of Aptuit progressing as planned Initial achievements & status quo Summary of transaction and Launch of INDiGO services in post-merger integration Q1 2018 Acquisition effective on Reducing time from nomina- 11 August 2017, approx. tion to regulatory submission 750 employees across 3
Slide 16: Clear targets, strong outlook for 2018
Clear targets, strong outlook for 2018 EVT Execute – Expected key milestones 2018 New long-term alliances integrating the offering of Aptuit, strategic launch of INDiGO New performance-based integrated technology/disease alliances Expansion of foundations and biotech network in USA/Europe Mi
Slide 17: Agenda
Agenda Highlights Q1 EVT Execute EVT Innovate Financial performance and outlook PAGE 16
Slide 18: Continued focus on accelerating EVT Innovate
Continued focus on accelerating EVT Innovate EVT Innovate – Key performance indicators Q1 2018 Revenues Adjusted EBITDA1) R&D expenses (in € m) (in € m) (in € m) 12.5 10.4 6.4 5.8 5.6 4.9 1.0 (2.4) (3.2) Q1 20162) Q1 20173) Q1 2018 Q1 20162) Q1 20173) Q1 2018 Q1 20162) Q1 20173) Q1 2018 Revenues i
Slide 19: Fully invested co-owned pipeline programmes
Fully invested > 80 co-owned pipeline programmes Partnership portfolio Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II EVT201 CNS – Insomnia EVT401 Immunology & Inflammation ND1) Oncology ND1) Oncology Clinical Various Women’s health – Endometriosis Various Women
Slide 20: Focus on accelerating innovation
Focus on accelerating innovation EVT Innovate – Major achievements Q1 2018 PAGE 19
Slide 21: Global leadership in iPSC
Global leadership in iPSC Strong focus on iPSC1) platform “IPS cells can become a powerful tool to develop new drugs to cure intractable diseases because they can be made from patients’ somatic cells.” Shinya Yamanaka Disease-specific drugs Screening Patient Disease Patient- in a dish specific iPSCs
Slide 22: One big effort for the benefit of many – Sanofi & Evotec
One big effort for the benefit of many Sanofi & Evotec – Transaction expected to close in H1 2018 Pipeline-building collaboration in infectious diseases (ID) Strong and diverse portfolio of > 10 research and early-stage development projects licensed from Sanofi to Evotec (EVT Innovate) – Sanofi will
Slide 23: Strong focus on BRIDGE initiatives in Q1 2018
Strong focus on BRIDGE initiatives in Q1 2018 LAB282 and LAB150 – Key parameters and status quo Basic Applied Technology Development Product Commercialisation Market Entry & Research Research and Demonstration and Market Development Market Volume Public Market Established in November 2016 Establ
Slide 24: More to come in EVT Innovate
More to come in EVT Innovate EVT Innovate – Expected key milestones 2018 New clinical initiations and good progress of clinical pipeline within existing partnerships Expansion of academic BRIDGE network Strong R&D progress within Cure X/Target X platforms and new EVT Innovate partnerships St
Slide 25: Agenda
Agenda Highlights Q1 EVT Execute EVT Innovate Financial performance and outlook PAGE 24
Slide 26: Good performance with new business mix, milestones still missing in Q1 2018
Good performance with new business mix, milestones still missing in Q1 2018 Condensed income statement Q1 2018 – Evotec AG and subsidiaries in € m1) Q1 2018 Q1 20174) % vs. 2017 Group revenue growth mainly due to good performance in the Revenues 79.0 50.9 55% base business and contribution from Ap
Slide 27: EVT Execute expanded, EVT Innovate on strategy
EVT Execute expanded, EVT Innovate on strategy Segment information Q1 2018 – Evotec AG and subsidiaries in € m1) Inter- Revenue growth in EVT EVT EVT segment Evotec Execute driven by Execute Innovate elimination Group performance in the base business and contribution Revenues 78.5 10.4 (9.9) 79.0
Slide 28: Revenues & Gross margin overview
Good underlying operational performance, contribution of Aptuit reflects new business mix Revenues & Gross margin overview Group revenues Gross margin1) Revenue growth due to strong (in € m) (in %) performance in the base business and positive contribution from Base revenues Total Margin Aptuit (€
Slide 29: "3x30" guidance confirmed
“3x30” guidance confirmed Guidance 2018 Double- 1 digit top- More than 30% Group revenue growth line growth Profitable Adjusted Group EBITDA1) expected to improve by approx. 30% 2 and growing compared to 2017 Focused 3 Group R&D expenses of € 20-30 m investments PAGE 28 1) Before contingent co
Slide 30: Important next dates
Important next dates Financial calendar 2018 Annual Report 2017 28 March 2018 Quarterly Statement Q1 2018 09 May 2018 Annual General Meeting 2018 20 June 2018 Half-year 2018 Interim Report 09 August 2018 Quarterly Statement 9M 2018 13 November 2018 PAGE 29
Slide 31: HRESEARCHNEVE
HRESEARCHNEVE ASTOPS